Markets

Ruthigen-Pulmatrix Merge, Focus on Respiratory Drugs - Analyst Blog

A generic image of a monitor with Market Analysis displayed
Credit: Shutterstock photo

Ruthigen, Inc.RTGN and Pulmatrix, Inc. announced that they have entered into a definitive merger agreement on Mar 13, 2015.

Upon closing of the transaction, Pulmatrix will become a wholly-owned subsidiary of Ruthigen, which will be renamed as Pulmatrix. Following NASDAQ's approval, the surviving company's common stock will continue to trade on The NASDAQ Capital Market. It will be headquartered in Lexington, MA.

Pulmatrix's debt and equity securities outstanding before the closing of the agreement will be exchanged for shares of Ruthigen common stock representing nearly 81% of the latter's outstanding common stock. In Feb 2015, Pulmatrix raised approximately $4.5 million in consideration of the upcoming merger with Ruthigen.

Additionally, some existing institutional investors in Pulmatrix entered into stock purchase agreements with the company to invest an additional amount of $10 million upon the closing of the merger. Ruthigen's shares surged 10.7% following the company's announcement.

Ruthigen stated that the combined company is expected to focus its resources on the development of Pulmatrix's next-generation inhaled therapeutic products. The merger will create a strong financial foundation and offer enhanced access to capital for the development of innovative inhaled products designed to meet significant unmet needs in the field of respiratory diseases. Moreover, it will provide the opportunity to advance Pulmatrix's iSPERSE inhaled dry powder platform and the lead cystic fibrosis candidate into clinical development.

Ruthigen carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the health care sector are Lannett Company, Inc. LCI , Salix Pharmaceuticals Ltd. SLXP and Cytokinetics, Inc. CYTK . All these stocks carry a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

RUTHIGEN INC (RTGN): Get Free Report

SALIX PHARM-LTD (SLXP): Free Stock Analysis Report

CYTOKINETCS INC (CYTK): Free Stock Analysis Report

LANNETT INC (LCI): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

CYTK LCI

Other Topics

Stocks

Latest Markets Videos

Zacks

Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

Learn More